Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug
• CSL Limited retains rights to clazakizumab in end-stage kidney disease. • Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in compet